DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20164093

Screening of a novel furan compound for its antidepressant activity in albino mice

Jayakumar JK, Supriya ., Nityakarnam ., Kishorekumar .

Abstract


Background: Depression is a common chronic recurrent syndrome, characterized by apathy, loss of energy, retardation of thinking and activity, as well as profound feelings of gloominess, despair and suicidal ideation. The present study aimed to evaluate the antidepressant activity of synthesized novel furan compound by using forced swimming test (FST) and tail suspension test (TST).

Methods: The antidepressant activity was studied in albino mice using FST and TST. Fluoxetine (20 mg/kg) were used as standard drugs and test drug novel furan compound (5, 10, 20 mg/kg) was used as test drug. A total of 60 mice were selected for the study and utilized 30 mice in each model. Animals were divided into five groups consisting of 6 animals in each. Control group received 10% tween 80 orally; standard group received fluoxetine 20 mg/kg orally; test group 1 received 5 mg/kg substituted furan compound orally; test group 2 received 10 mg/kg substituted furan compound orally; test group 3 received 20 mg/kg substituted furan compound orally.

Results: In FST the low dose test compound had shown the percentage inhibition of 75.5% which was comparable to percentage inhibition of standard drug fluoxetine -82%. In TST the test group-1 had produced 66.6%, test group-2 83.3% and test group-3 produced 100% protection against passive behavior (immobility). The percentage of protection produced by highest dose was equal to standard drug fluoxetine against passive behavior.

Conclusions: It can be concluded that the test drug has produced significant inhibition in duration of immobility by FST and also had significant protection against passive behavior. Hence substituted furan had potential antidepressant activity.


Keywords


Antidepressant activity, Novel furan compound, FST, TST

Full Text:

PDF

References


Lopez AD, Murray CJ. The global burden of disease, 1990–2020. Nature medicine. 1998;4(11):1241–3.

Londhe VP, Nipte SS, Bandawane DD, Chaudhari PD. Screening methods of antidepressants with an Epigrammatic record of research did on Herbal and synthetic drugs. IJPI’S J pharmacol Toxicol. 2011;1(5):61-74.

Meti V, Ruckmani A, Chandrashekar K, Konda VGR, Madhavi E, Swati B, et al. Antidepressant activity of ethanolic extract Piper betle leaves in mice. Current Res Neurosci. 2012;2(1):11-6.

Gireesh KS, Debapriya G, Muruganandam AV, Vinod KJ, Sairam K. Antidepressant activity of Asparagus racemosus in rodent models. Pharmacol Biochem Behav. 2009;91:283-90.

Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977;229:327–36.

Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacol (Berl). 1985;85:367–70.

Ashok Kumar BS, Lakshman K, Velmurugan C, Sridhar SM, Gopisetty S. Antidepressant Activity of Methanolic Extract of Amaranthus Spinosus. Basic Clin Neurosci. 2014 Winter; 5(1):11–7.

Ahmed Amany AE, Al-Rashed Nawal M, Al-Rasheed Nouf M. Antidepressant-like activities of rosiglitazone in the rat forced swim and the mouse tail suspension tests. Saudi Pharma J. 2009;1(17):51–61.

Plaznik A, Tamborska E, Hauptmann M, Bidzinski A, Kostowski W. Brain neurotransmitter systems mediating behavioral deficits produced by inescapable shock treatment in rats. Brain Res. 1988;447:122–32.

Manavi C, Pinki V, Gautam P. Comparative evaluation of Bacopa monniera and Panax quniquefolium in experimental and depressive models in mice. Indian J Exp Biol. 2010;48:306–31.

Ramana Murty Kadali SLDV, Das MC, Srinivasa Rao ASR, Karuna Sri G. Antidepressant Activity of Brahmi in Albino Mice. J Clin Diagn Res. 2014;8(3):35-7.